A compilation of news articles in the field of gynecologic oncology and recent scientific studies
Retroperitoneal exploration improves survival in optimally debulked advanced epithelial ovarian cancer.
February 6, 2017: “Retroperitoneal exploration at the time of primary debulking surgery appeared to improve survival in patients with intraperitoneal stage IIIC optimally debulked epithelial ovarian cancer, according to data collected from a large multi-institutional trial.” Read more.
Dr. Levine on combos with PARP inhibitors in ovarian cancer
February 3, 2017: Dr. Douglas Levine on OncLive discusses combining PARP inhibitors with chemotherapy as well as the question of when and how to give them. View the video.
Diagnostic laparascopies can prevent future surgeries in ovarian cancer
February 1, 2017: A study published in the Journal of Clinical Oncology shows that “the number of futile laparotomies was decreased in patients with advanced stage ovarian cancer who underwent diagnostic laparoscopies.” Read more.
Homologous recombination deficiency analysis predicts PARP inhibitor benefit for ovarian cancer
January 27, 2017: “Next-generation sequencing used to detect homologous recombination deficiency may predict responses to rucaparib in patients with BRCA wild-type platinum-sensitive ovarian cancers, according to results from the international, multicenter, open-label phase 2 trial ARIEL2 study.” Read more.
Lynch syndrome – associated ovarian cancer presents early, has good prognosis
January 25, 2017: An analysis of Lynch syndrome–associated ovarian cancer published in Gynecologic Oncology found that the malignancy tends to present at an early stage and has a generally good prognosis. Ovarian surveillance may be useful in some women to detect this malignancy early. Read more.
Murine study finds potential boost for ovarian cancer drug Olaparib
January 25, 2017: “Researchers have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings suggest that this FDA-approved ovarian cancer medicine has the potential to treat a wider range of cancer types than currently indicated.” Read more about this study.
TCGA study identifies genomic features of cervical cancer
January 24, 2017: A news release from the National Institutes of Health announces “investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies that are most appropriate for each patient.” Read more.
Study pinpoints opportunity for oncologists to improve communication with patients.
January 24, 2017: A study published in the Journal of Oncology Practice looked at doctor-patient conversations and found that doctors naturally avoid difficult discussions about a challenging prognosis. This shows there may be missed opportunities to discuss what test results actually mean and allow the patient and family members to process and explore the situation. Read more.
Cervical cancer deaths rates are much higher than previously thought
January 23, 2017: “Black women are dying from cervical cancer at a rate 77% higher than previously thought, and white women are dying at a rate 47% higher, according to a study published in the journal Cancer. The study found that previous estimates of cervical cancer death rates didn’t account for women who had their cervixes removed in hysterectomy procedures, which eliminates the risk of developing the cancer.” Read more.
Endometrioid ovarian cancer presents earlier, offers better survival than serous carcinoma
January 20, 2017: “Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.” Read more.
Countries with limited health care resources need education regarding breast cancer risk factors
January, 2017: Survey reveals there is a need for breast cancer education in limited resource countries. Read more.
Ovarian conservation may boost outcomes in endometrial cancer
January 18, 2017: MedPage Today (free login required) writes, “Ovarian conservation was associated with decreased long-term all-cause mortality in young women with low-grade, early-stage endometrial cancer,, according to researchers.” Read more.
Why are we still talking about ‘ovarian’ cancer?
January 18, 2017: Seventy-five percent of the most deadly ‘ovarian’ cancer arises in the fallopian tubes. Should the new name for ovarian cancer be pelvic serous carcinoma? Read more.
More Chemo may not equal better outcomes in ovarian cancer
January 16, 2017: MedPage Today (free login required) writes “Increasing, the number of cycles of chemotherapy doesn’t appear to significantly influence recurrence rates or survival in patients with early stage ovarian clear cell carcinoma (OCCC), according to researchers.” Read more.
Assessment identifies patients with endometrial cancer at low risk for lymph node metastasis
January 13, 2017: “Preoperative assessment of lymph node metastasis in endometrial cancer may encourage selective lymphadenectomy for low-risk patients,” according to a study by Dr. Sokbom Kang and colleagues at the Research Institute and Hospital of National Cancer Center in the Republic of Korea. Read more.
Research evaluates treatment options for pelvic organ prolapse
January 12, 2017: Recently published in the American Journal of Obstetrics & Gynecology, research “found that while women undergoing surgery or having a pessary achieve their goals and have improvements in physical, social and emotional functioning, those who underwent surgery experienced greater improvements.” Read more.
Researchers discover new subtype of cervical cancer
January 10, 2017: “A team of University of South Carolina scientists led by Carolyn Banister and Phillip Buckhaults has identified a new subtype of cervical cancer that, like most cervical cancers, is triggered by human papillomavirus (HPV) but whose growth is not directed by the virus, suggesting that therapy targeting these tumors’ distinct genomic pathways may improve patient outcomes over standard treatment.” Read more.